Cefsulodin

In patients undergoing haemodialysis: 1 g is given before and after dialysis.

CrCl (mL/min)	Dosage
<5	Loading dose: 1.5 g, then 1 g every 24 hr.
20-50	Loading dose: 1.5 g, then 1 g every 8 hr.
5-20	Loading dose: 1.5 g, then 1 g every 12 hr.

Hypersensitivity to cephalosporins.

Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status.

Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction; haematologic disorders; pain at inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.
Potentially Fatal: Pseudomembranous colitis.

Reduced renal clearance when used with probenecid.
Potentially Fatal: Increased risk of nephrotoxicity when used with aminoglycosides or loop diuretics.

Description:
Mechanism of Action: Cefsulodin has a narrow spectrum of activity. It is active against P. aeruginosa (which can be enhanced by aminoglycosides) but no significant activity against other gram-negative bacteria. Gram-positive bacteria and anaerobes are not very susceptible. It is also stable to hydrolysis by many β-lactamases.
Pharmacokinetics:
Distribution: Up to 30% bound to plasma proteins.
Excretion: Plasma half-life of about 1.6 hr; prolonged in renal impairment. Mainly excreted via urine.

Cephalosporins